



Executive Summary

Introduction

Vivakor™ (VIVK.OB) is a biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. Scientists at Vivakor (the idea hub) innovate, develop and validate biomedical devices and biotechnologies. Commercialization of Vivakor technologies is accomplished through partnerships with manufacturers and niche-industry marketing and distribution leaders. Vivakor generates revenues through the licensing or acquisition of its technologies. Vivakor is preparing a portfolio of IP and wholly owned subsidiaries. These will focus on the commercialization of technologies developed by Vivakor.

Company Mission

Inventing Solutions for Life--The development of effective technologies and cures requires contribution from many scientific disciplines—we call this transdisciplinary R&D. Vivakor mission is to advance this type of R&D and rapidly bring products to market through multiple commercialization strategies.

History

Vivakor was founded in 2006 as a Nevada LLC and was converted to a Nevada C-Corporation in 2008. Its initial registration statement on Form S1 was declared effective by the SEC in December 2008.

Strengths

- Rapidly growing intellectual property assets
- Products tested by Academic and Industry collaborators
- Products in clinical validation testing
- Long-term products and vision fueled by short-term product revenue potential
- Adaptable transdisciplinary R&D Scientific Team
- Integration of business and scientific R&D into one team
- Collaborations with premier scientists

Hub & Spoke Business Model

- Vivakor is the idea HUB of R&D
- SPOKES developing multiple products for market
- Products may be licensed, acquired or spun-off
- Product-specific exits

Company Profile

Vivakor™ Inc. (VIVK.OB)

- ✓ **Founded 2006 as Nevada LLC**
- ✓ **Converted C-Corp 2008**
- ✓ **S1 Effective December 2008**

Address

2590 Holiday Road Ste 100
Coralville, IA 52241
www.vivakor.com

Point of Contact

Matt Nicosia
Executive Chairman
mnicosia@vivakor.com
(949) 887-6890

Industry

Biotechnology/Biomedical Device

Technologies

- ✓ **VivaSight**
 - Child vision screening
 - Clinical Testing & 510k Validation
- ✓ **VivaThermic**
 - Bio-consumables
 - Launched in Q1 2009
- ✓ **VivaBlend**
 - Multi-Plant Super Anti-oxidant Extract
 - Launched June 09
- ✓ **VivaSlices**
 - MRI resolution enhancer
 - Production and re-validation

Products in Development

- Clinical Bio-molecular Sensor**
 - ✓ Point of care molecular diagnostic
- Anemia & Wound Monitor**
 - ✓ Clinical Testing
- Burn and Melanoma MSI**
 - ✓ Collaborating with University researchers/clinicians

Intellectual Property

Multiple Patents Pending
Secured trade secrets

Current Funding Goal

\$3.5 Million equity capital

Use of Funds

Working Capital
Product Development
Clinical Validation
R&D Operations

Product Commercialization

Vivakor commercializes its products through three primary modes:

1. Product Licensing and joint ventures with manufacturers, marketing/distribution partners
2. Technology Acquisition
3. Technology spin-off in a subsidiary

This versatility allows production of Vivakor-labeled products as well as OEM private label products. Vivakor streamlines R&D inputs to accelerate conceptualization, prototyping and validation leading to more rapid and efficient commercialization.

Technology Spokes

Molecular Medicine-

- ✓ Customized molecular medicine
- ✓ Focus on cancer detection and wound healing
- ✓ Developing proprietary wound healing system that mimics fetal wound healing
- ✓ Researching stem cell therapies and genetic reprogramming

Electro-Optics-

- ✓ Designing, building and testing new electro-optic biomedical devices
- ✓ Will spin-off **VivaSight**, **Health America (VivaSlices)** and **VivAuris**
- ✓ Developing Clinical Bio-molecular Sensor and Multispectral Imaging of burns and melanoma

Biological Handling-

- ✓ Better performing bio-consumables and sample handling technologies
- ✓ Spun-off **VivaThermic**
- ✓ Developing technologies to better cryopreserve tissue (e.g. biopsies) and human stem cells

Natural and Formulary Products-


- ✓ Isolating new botanical actives for use in supplements and Nutraceuticals
- ✓ Developed and has taken to market **VivaBlend** a super enriched anti-oxidant plant extract
- ✓ Currently developing anti-viral supplements

Contract Research Services-

- ✓ Contracted to perform several cosmaceutical validation studies
- ✓ Offer custom engineering (mechanical/electrical) engineering services
- ✓ Develop custom tests (e.g. Vivakor's TO₂PICAL™ oxygen permeability test)
- ✓ Apply for government contracts (e.g. National Cancer Institute and the Center for Disease Control--CDC)

Vivakor Near-Term Spin-off Subsidiaries

1. **VivaThermic.** VivaThermic technologies were developed in Vivakor's Biological Handling division. VivaThermic products include a temperature conductive vial, CryoKeeper and CryoCarrier. Improved biological sample preservation has been the driving force behind the innovative products. Together these technologies allow for improved sample cryopreservation and thawing crucial for cell viability. The application of these products maintains a very broad use (e.g. clinical laboratories, hospitals, fertility clinics, veterinarians, and research laboratories). These products form a family which can function independently or as a system. Provisional patents have been filed on each product.



STATUS: Product launch is anticipated for **September 2009**.

2. **VivaSight.** VivaSight technology (device, software and accessories) will modernize child vision screening. Vivasight digitizes and automates the data interpretation allowing for minimal training required and limited additional costs. Demand for these products, developed in the Electro-Optics division of Vivakor, is high and will continue to grow as more states begin to mandate pre-kindergarten vision screening. Provisional patents have been filed on both the apparatus and the software. **STATUS:** VivaSight is currently in clinical validation at the University of Iowa. Product launch is anticipated in **Spring 2010**.

ESTIMATED GROWTH				
Vivakor Products Target High Potential Markets				
Vivakor Products/ Subsidiary	Estimated Years to Market #	Estimated Years to Profitability*	Capital Required [^]	5 Year Estimated Revenues*
Viva Thermic	0.00	0.75	\$2.0M	\$50M
VivaSight	0.50	1	\$2.0M	\$150M
Vivablend	0.00	0.5	\$2.0M	\$100M
VivaSlices	0.50	0.5	\$3.0M	\$300M
Wound Monitor	1.00	1	\$2.0M	\$25M
VivAuris	1.00	1	\$3.0M	\$75M
Anema Monitor	1.25	1	\$2.0M	\$40M
MSI Platform				
Melaoma Detector	3.00	2	\$5.0M	\$35M
Burn Classifier	3.50	2	\$5.0M	\$30M
Clinical Sensors (CBS)	5.00	2	\$30.0M	\$800M
# After full funding to Capital Requirement * After Product Reaches Market ^ To Reach Profitability				

3. **VivaBlend.** Vivakor has developed a proprietary patent-pending (#61093311) nutraceutical formulation of natural plant anti-oxidants and anti-inflammatory extracts. Vivakor is now developing food products that will include this natural supplement. **STATUS:** VivaBlend launched in **June 2009**.
4. **VivaSlices.** Health America will be the second spin-off from Vivakor's Electro-Optics division. VivaSlices technology is a software upgrade to older MRI units that allows the unit to achieve higher resolution by using a patented algorithm. VivaSlices also applies to CAT Scanners and indications have shown the technology to be used in blood flow analysis. **STATUS:** VivaSlices is going through a software upgrade and is anticipated to launch in **Spring 2009**.

Vivakor Technologies in Development

- ❖ **Anemia Monitor.**
 - Enables clinicians or patients at home to measure and track anemia
 - Non-invasive, non-contact device to complement Complete Blood Count measures
 - Reduce the number of blood draws for anemic patients
- ❖ **Wound Monitor.** (*Patent Pending #61052422*)
 - Enables clinicians and patients at home to monitor wound recovery
 - Early detection of diabetic ischemic ulcers (e.g. foot ulcers) before the skin is broken
 - Detection of pressure ulcers (e.g. bed sores) before to skin rupture
 - Monitoring recovery from cosmetic surgery
 - Currently in clinical validation
- ❖ **MSI (Multi-Spectral Imaging).**
 - Non-invasive medical imaging technology platform
 - Assist in the detection of early stage melanoma
 - Assist in classification of in-determinant burns as full or partial thickness
 - Collaborating with University of Iowa Melanoma Clinic & University of Iowa Burn Center
- ❖ **CBS (Clinical Biomolecular Sensor).** (*Patent Pending #61044472*)
 - Point-of-care biomolecular diagnostic platform
 - Lable-free, Real-time detection using a multiplex of sample interrogants
 - More sensitive and portable than surface plasmon resonance

Exit Strategies

Vivakor is the idea core growing diversified product spokes which lead to the following technology-focused exits: 1) product licensing, 2) technology acquisition, or 3) subsidiary spin-off. In addition, the core parent company is publicly traded on the OTCBB on the ticker of VIVK.

Management

Vivakor™ benefits from the integration of its business and scientific R&D team. Vivakor executives and members of the R&D team have worked together in previous ventures over the past nine years and have established solid professional and personal interrelationships.

Dr. Tannin Fuja, PhD, CEO, Chief Scientist and Director- In this capacity he directs all scientific research and business development for Vivakor™, Inc. As a published scientific investigator, Dr. Fuja has a broad experience in the application of molecular methodologies relating to complex human diseases and development including a wide spectrum of specialties from human cancer biology to stem cell research.

Mr. Matt Nicosia, Executive Chairman of the Board- Mr. Nicosia is one of our founders and is one of those rare business men who combines top management skills with true entrepreneurship to inspire, challenge and motivate employees and business partners. He has founded several other businesses and currently sits on the Board of Directors. Mr. Nicosia is a principal of Integrity Equity, a business development group specializing in assisting young companies in high growth markets and sits on the board of several private companies.

Mr. Ed Corrente, CPA, CFO- Mr. Corrente's experience includes working with high-growth companies in all aspects of finance, accounting and internal controls and has been involved in acquisitions, dispositions, due diligence, public and private financing and SEC filings in transactions aggregating well over \$2 Billion.

Dr. YingYing Zhou, PhD Cryobiology Program Manager- Dr. Zhou earned her Doctoral degree in Mechanical Engineering from UC Berkeley and has over ten years of industry experience. Five of those years in Research and Development, product testing, protocol, and manufacturing process design.

Mr. Christopher A. Wilson, Esq. (Corporate Legal Counsel) Wilson, Haglund & Paulsen, P.C. (Irvine, CA)

Mr. Michael Ries (Patent Counsel) Michael Ries & Associates (Chicago, IL)

Seeking- \$3.5 million to operate through March of 2010.

Use of proceeds:

- \$300k → VivaSight completion of production model and regulatory clearance
- \$700k → Re-formatting and re-validation of VivaSlices software
- \$1m → VivaSlices Commercialization
- \$500k → VivaThermic manufacturing and commercialization
- \$300K → VivAuris manufacture
- \$700K → Administrative operations and filings



Vivakor™ was established with the ideal and unifying mission of inventing solutions for life.